Category: Regulatory DisclosuresBy adminFebruary 2, 2021 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:EGX Disclosure on BOD and shareholding structureNextNext post:Disclosure to EGX on GlaxoSmithKline S.A.E response to Rameda’s acquisition requestRelated PostsBOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024Rameda 4Q23 BOD Meeting MinutesMarch 18, 2024BOD Report FY2023- under the Regulatory DisclosuresMarch 18, 2024Annual Corporate Governance Disclosure ReportMarch 18, 2024
